Dr. Antonio Calles 🫁🚭· @Tony_Calles · X·· 1 天前评分45
正文 · 原文
Dr. Egbert Smit cooling down expectations on ADCs in NSCLC.
☑️ Biomarker driven selection needed.
☑️ Mechanistic explanation on outcomes by different payloads
☑️ SCC histology to be excluded from Trop2 ADCs given the detrimental efficacy
#ESMO26 #LCSM
11 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
2631RO按 Rapid oral 1: NSCLC, metastatic 对上
First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.org来源：Dr. Antonio Calles 🫁🚭 · x.com